13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q3 2020. See the latest, Q2 2026 →

Reported value

$2.13B

−1.8% on the quarter before

Positions

3 new · 3 sold out

Top 10

96.0%

of the value

Est. gain

+$111.4M

on stocks held all quarter

Est. return

+5.9%

on those stocks since Q2 2020

Filed

Nov 15, 2022

On SEC EDGAR ↗

Positions as of Sep 30, 2020, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2020. Striped tiles are options.

Jd Com Inc49%

Lyft Inc17%

Dexcom Inc16%

Arcus Biosciences Inc4.1%

Relay Therapeutics Inc3.6%

Lemonade1.9%

Slack Technologies Inc.1.6%

Rapt Therapeutics Inc1.3%

Magenta Therapeutics Inc1.1%

0.8%

0.7%

0.6%

Jd Com Inc49%

Lyft Inc17%

Dexcom Inc16%

Arcus Biosciences Inc4.1%

Relay Therapeutics Inc3.6%

Lemonade1.9%

Slack Technologies Inc.1.6%

Rapt Therapeutics Inc1.3%

Magenta Therapeutics Inc1.1%

0.8%

0.7%

0.6%

Largest buys

Since Q2 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Relay Therapeutics Inc~$76.7MNew · 0.0% → 3.6%+1,801,490 shares
Lemonade~$41.0MNew · 0.0% → 1.9%+824,743 shares
Taysha Gene Therapies Inc~$14.4MNew · 0.0% → 0.7%+640,882 shares

Largest sells

Since Q2 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

1life Healthcare Inc~$224.6MSold out · 10.4% → 0.0%−6,183,154 shares
Schrödinger~$41.1MSold out · 1.9% → 0.0%−448,722 shares
Snap~$12.3MSold out · 0.6% → 0.0%−523,710 shares
Mohawk Group Hldgs Inc~$1.3MCut · 0.3% → 0.3%−155,236 shares
Gritstone Oncology Inc~$1.0MCut · 0.3% → 0.1%−381,534 shares
Fulcrum Therapeutics Inc~$32,507Cut · 0.6% → 0.3%−4,099 shares

Holdings

As of Sep 30, 2020. Changes are in shares against Jun 30, 2020, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Jd Com IncSPON ADR CL A · shares 0% · price +29.0%	49.4%	37.6%	$1.05B	13.6M	0%	$77.61	$60.18	+29.0%	+$236.2M
2	Lyft IncCL A COM · shares 0% · price −16.5%	16.6%	19.5%	$353.4M	12.8M	0%	$27.55	$33.01	−16.5%	−$70.0M
3	Dexcom IncCOM · shares 0% · price +1.7%	15.6%	15.1%	$332.1M	805,681	0%	$412.23	$405.40	+1.7%	+$5.5M
4	Arcus Biosciences IncCOM · shares 0% · price −30.7%	4.1%	5.8%	$86.6M	5.0M	0%	$17.14	$24.74	−30.7%	−$38.4M
5	Relay Therapeutics IncCOM · shares New	3.6%	—	$76.7M	1.8M	New	$42.59	—	—	—
6	LemonadeCOM · shares New	1.9%	—	$41.0M	824,743	New	$49.72	—	—	—
7	Slack Technologies Inc.COM CL A · shares 0% · price −13.6%	1.6%	1.9%	$34.9M	1.3M	0%	$26.86	$31.09	−13.6%	−$5.5M
8	Rapt Therapeutics IncCOM · shares 0% · price +11.0%	1.3%	1.1%	$26.9M	836,059	0%	$32.20	$29.02	+11.0%	+$2.7M
9	Magenta Therapeutics IncCOM · shares 0% · price −9.5%	1.1%	1.2%	$22.7M	3.3M	0%	$6.80	$7.51	−9.5%	−$2.4M
10	Beam Therapeutics IncCOM · shares 0% · price −12.1%	0.77%	0.86%	$16.3M	663,691	0%	$24.62	$28.00	−12.1%	−$2.2M
11	Taysha Gene Therapies IncCOM SHS · shares New	0.67%	—	$14.4M	640,882	New	$22.40	—	—	—
12	Spero Therapeutics IncCOM · shares 0% · price −17.5%	0.58%	0.69%	$12.4M	1.1M	0%	$11.16	$13.53	−17.5%	−$2.6M
13	Ideaya Biosciences IncCOM · shares 0% · price −11.6%	0.44%	0.49%	$9.5M	753,187	0%	$12.56	$14.21	−11.6%	−$1.2M
14	Cortexyme IncCOM · shares 0% · price +8.0%	0.44%	0.40%	$9.5M	189,122	0%	$50.00	$46.30	+8.0%	+$700,000
15	Autolus Therapeutics PlcSPON ADS · shares 0% · price −27.4%	0.38%	0.52%	$8.1M	698,262	0%	$11.64	$16.03	−27.4%	−$3.1M
16	Mohawk Group Hldgs IncCOM · shares −15% · price +50.3%	0.35%	0.27%	$7.4M	900,718	−15%	$8.25	$5.49	+50.3%	+$2.5M
17	Evelo Biosciences IncCOM · shares 0% · price +7.6%	0.26%	0.24%	$5.6M	1.1M	0%	$5.27	$4.90	+7.6%	+$393,000
18	Fulcrum Therapeutics IncCOM · shares −0.6% · price −56.6%	0.25%	0.58%	$5.4M	678,141	−0.6%	$7.93	$18.29	−56.6%	−$7.0M
19	Cloudera IncCOM · shares 0% · price −14.4%	0.22%	0.25%	$4.7M	427,710	0%	$10.89	$12.72	−14.4%	−$782,000
20	CrowdStrikeCL A · shares 0% · price +36.9%	0.20%	0.14%	$4.3M	31,020	0%	$137.33	$100.29	+36.9%	+$1.1M
21	Alector IncCOM · shares 0% · price −56.9%	0.09%	0.20%	$1.9M	175,866	0%	$10.54	$24.44	−56.9%	−$2.4M
22	UberCOM · shares 0% · price +17.4%	0.07%	0.06%	$1.5M	41,585	0%	$36.48	$31.07	+17.4%	+$225,000
23	Gritstone Oncology IncCOM · shares −41% · price −60.1%	0.07%	0.28%	$1.5M	547,488	−41%	$2.65	$6.64	−60.1%	−$2.2M
24	Dropbox IncCL A · shares 0% · price −11.6%	0.01%	0.01%	$251,000	13,033	0%	$19.26	$21.79	−11.6%	−$33,000
	Total · 24 positions	100%		$2.13B						+$111.4M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2020 to Q3 2020: 21 stocks held throughout, up $111.4M (+5.9%).

Jd Com Inc+$236.2M+29%
Dexcom Inc+$5.5M+2%
Rapt Therapeutics Inc+$2.7M+11%
Mohawk Group Hldgs Inc+$2.5M+50%
CrowdStrike+$1.1M+37%
Autolus Therapeutics Plc−$3.1M−27%
Slack Technologies Inc.−$5.5M−14%
Fulcrum Therapeutics Inc−$7.0M−57%
Arcus Biosciences Inc−$38.4M−31%
Lyft Inc−$70.0M−17%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗